Trial · NCT04117698
Registered outcomes46
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 46
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Success | at 18 months | Success is defined by uveitis recovery at 3 months and the absence of recurrence at 18 months of follow-up. The intensity of the ocular inflammation will be evaluated using the Standardization of Uveitis Nomenclature (SUN) classification (score of cellular Tyndall and "Flare" of the aqueous humor) Failure is therefore defined as failure to recovery at 3 months of anterior uveitis or recurrence at 18 months. |
| Secondary | Proportion of patients having developped neutropenia | at 6 months | Neutropenia will be defined as PNN less than 1000 mm3 |
| Secondary | Proportion of patients having developped hepatitis with clinical signs | at 6 months | Hepatitis will be defined as hepatitis with clinical signs and ALT greater than 3 times the normal value |
| Secondary | Proportion of patients having developped severe hepatitis | at 6 months | Severe hepatitis will be defined will be defined as ALT greater than 5 times the normal value |
| Secondary | Proportion of patients having developped moderate or severe skin allergy | at 6 months | |
| Secondary | Proportion of patients having developped neuritis or optic atrophy | at 6 months | |
| Secondary | Proportion of patients having developped acute renal failure | at 6 months | |
| Secondary | Proportion of patients having developped peripheral neuropathy | at 6 months | |
| Secondary | Proportion of patients having developped other adverse effects | at 6 months | |
| Secondary | Proportion of patients with recurrence | between 3 months and 18 months | |
| Secondary | Prevalence of failure | at 12 months post-treatment | |
| Secondary | Cumulative incidence of episodes of ocular inflammation | at 18 months | |
| Secondary | Cumulative number of anterior uveitis episodes | at 18 months | |
| Secondary | Tyndall score | at 1 month | |
| Secondary | Flare's score | at 1 month | |
| Secondary | Tyndall score | at 2 months | |
| Secondary | Flare's score | at 2 months | |
| Secondary | Tyndall score | at 3 months | |
| Secondary | Flare's score | at 3 months | |
| Secondary | Tyndall score | at 6 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04117698/registered